Sigachi Industries Limited (NSE: SIGACHI, BSE: 543389) is a Hyderabad, Telangana-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹1,054 Cr, it ranks #1,551 by market cap among the 6,197 Indian listed companies on FinBizNet, and #46 of 86 in Medicinal Chemicals and Botanical Products. At ₹28.60 (as of 16 Nov 2026), the share price is 29.9% below its 52-week high of ₹40.80 and 71.8% above its 52-week low of ₹16.65. The share price is down 20.4% over one year and up 2.6% over three months.
| Current Price | ₹28.60 |
|---|---|
| Market Cap | ₹1,054 Cr |
| NSE Symbol | SIGACHI |
| BSE Code | 543389 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | Not meaningful (loss) |
| Return on Equity | -14.50% |
| Return on Assets | 2.69% |
| 52-Week Range | ₹16.65 – ₹40.80 |
| 1-Year Price Change | -20.4% |
| 3-Month Price Change | +2.6% |
| Beta (1Y) | 0.45 |
| Dividend Yield | 0.36% |
| Headquarters | Hyderabad, Telangana |
| Website | sigachi.com |
| Revenue | ₹130 Cr |
|---|---|
| Net Profit | ₹9 Cr |
| Net Margin | 6.7% |
| EPS (Basic) | ₹0.27 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Sigachi Industries Limited reported revenue of ₹130 Cr in Q2 FY27, up 18.1% from ₹110 Cr in Q2 FY26 and up 7.6% from ₹121 Cr in Q1 FY27. It posted a net profit of ₹9 Cr for the quarter, against a net profit of ₹11 Cr in Q2 FY26 (down 16.6%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹110 Cr (Q2 FY26) to ₹130 Cr (Q2 FY27). The company reported a net loss in 2 of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹130 Cr | ₹9 Cr | 6.7% |
| Q1 FY27 | ₹121 Cr | ₹8 Cr | 6.7% |
| Q4 FY26 | ₹122 Cr | ₹8 Cr | 6.3% |
| Q3 FY26 | ₹117 Cr | −₹0 Cr | −0.0% |
| Q2 FY26 | ₹110 Cr | ₹11 Cr | 9.5% |
| Q1 FY26 | ₹128 Cr | −₹101 Cr | −78.7% |
| Q4 FY25 | ₹128 Cr | ₹16 Cr | 12.6% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 36.69% of Sigachi Industries Limited's shares as of Sept 2026, against 40.48% in Sept 2025 (−3.79 percentage points). Delivery averaged 42.2% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Sigachi Industries Limited manufactures and sells microcrystalline cellulose and cellulose powder in India. The company offers cellulose-based products under the HiCel, AceCel, CoatCel, GloCel, and BARETab names; and various chemicals, including colloidal silicon dioxide, carboxy cellulose sodium and mannitol, etc. to active pharmaceutical ingredients, food and nutrition, cosmetic, and chemical industries. It also provides operations and maintenance services in the fields of speciality chemicals, petrochemicals, water treatment, and pharmaceuticals. In addition, the company exports its products. Sigachi Industries Limited was incorporated in 1989 and is headquartered in Hyderabad, India.
1. Manufacturing & Supply of Microcrystalline Cellulose - Pharmaceutical Excipient-This segment manufactures and sells microcrystalline cellulose powder.
1. Manufacturing and Selling of MCC-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Sigachi Industries Limited | ₹1,054 Cr | n/m | -14.50% | ₹130 Cr | -20.4% |
Listed by market capitalisation. Ratios are shown for context only.
Sigachi Industries Limited is trading at ₹28.60, with a market capitalisation of ₹1,054 Cr.
Sigachi Industries Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Sigachi Industries Limited has a return on equity of -14.50%.
Sigachi Industries Limited is listed on the NSE under the symbol SIGACHI and on the BSE under the scrip code 543389.
Sigachi Industries Limited's share price is down 20.4% over one year and up 2.6% over three months. Its 52-week range is ₹16.65 to ₹40.80.
In Q2 FY27, Sigachi Industries Limited reported revenue of ₹130 Cr and net profit of ₹9 Cr, with basic EPS of ₹0.27 (consolidated, parsed from the company's exchange filing).
Sigachi Industries Limited reported revenue of ₹130 Cr in Q2 FY27, up 18.1% from ₹110 Cr in Q2 FY26 and up 7.6% from ₹121 Cr in Q1 FY27.
Promoters held 36.69% of Sigachi Industries Limited's shares as of Sept 2026, against 40.48% in Sept 2025 (−3.79 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.